Study wrapper · #43
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Editor's note
A systematic review worth reading for its transparency about evidence quality. Of 544 records, 36 studies met inclusion, but 35 were preclinical and only one was clinical, and the authors grade the body of work as level IV-V (the weakest tiers). In animal models BPC-157 was associated with improved functional, structural and biomechanical outcomes across muscle, tendon, ligament and bone, plausibly via growth-hormone-receptor and angiogenic pathways. The single human signal is a retrospective series in which 7 of 12 patients reported over six months of relief after intra-articular injection for chronic knee pain: hypothesis-generating at best, uncontrolled and small. Preclinical safety studies showed no adverse effects, but the authors stress no clinical safety data exist and flag contamination risk from unregulated sourcing. BPC-157 is not FDA-approved and is banned in professional sport.
Plain-language abstract
This is a systematic review, meaning the authors searched the medical literature methodically and pooled what they found. From 544 initial articles, 36 studies qualified, but 35 were in animals and only one involved people. In animal experiments, BPC-157 was linked to better healing of muscle, tendon, ligament, and bone, likely by boosting growth signals and blood-vessel formation. The one human study was a look-back at 12 patients who received a BPC-157 injection into the knee for chronic pain; 7 reported relief lasting more than six months. That is a weak, uncontrolled signal. Animal safety studies showed no harmful effects, but the authors emphasise there is no human safety data, and that products bought from unregulated sources may be contaminated. They advise caution, and note the peptide is banned in professional sports.